	Notice of References Cited		Application/Control No. 10/039,078	Applicant(s)/Patent Under Reexamination TUSZYNSKI, MARK H.	
			Examiner Anne-Marie Falk, Ph.D.	Art Unit 1632	Page 1 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,451,306	09-2002	Tuszynski et al.	424/93.21
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Anderson, W.F. (1998) Human gene therapy. Nature 392: 25-30.
	V	Friedmann (1997) Overcoming the obstacles to gene therapy. Scientific American, June 1997, pp. 97-101.
	W	Hodgson, CP (1995) Advances in vector systems for gene therapy. Exp. Opin. Ther. Patents 5(5): 459-468.
	X	Kumar et al. (1992) Basic Pathology, 5th Edition, W.B. Saunders Company, Philadelphia, pages 725-729.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

		Application/Control No.	Applicant(s)/Patent Under Reexamination
Notice of References Cited		10/039,078	TUSZYNSKI, MARK H.
		Examiner	Art Unit	Page 2 of 3
		Anne-Marie Falk, Ph.D.	1632	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Levi-Montalcini et al. (1996) Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 19(11): 514-520.
	V	Miller and Vile (1995) Targeted vectors for gene therapy. FASEB Journal 9: 190-199.
	W	Orkin and Motulsky (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Pages 1-37.
	X	Price et al. (1998) Genetic neurodegenerative diseases: The human illness and transgenic models. Science 282: 1079-1083.

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

		Notice of References Cited	Application/Control No. 10/039,078	Applicant(s)/Patent Under Reexamination TUSZYNSKI, MARK H.	
			Examiner Anne-Marie Falk, Ph.D.	Art Unit 1632	Page 3 of 3

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ross et al. (1996) Gene therapy in the United States: A five-year status report. Human Gene Therapy 7: 1781-1790.
	V	Rubanyi, GM (2001) The future of human gene therapy. Molecular Aspects of Medicine 22: 113-142.
	W	Verma et al. (1997) Gene therapy – promises, problems and prospects. Nature 389: 239-242.
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.